Foghorn Therapeutics has reportedly abandoned plans for its drug candidate to treat eye tumours after releasing Phase 1 data.
FHD-286 is an enzymatic inhibitor of BRG1 and BRM, two proteins that promote cancer cell growth.
According to news reports, the company said data released from a dose-escalation study in metastatic uveal melanoma showed that the drug “reinforces the safety and tolerability profile” of the candidate but will not be pursued further in this indication.
The trial assessed 73 patients with the retinal tumour who received one of nine different regimens, including one of four different FHD-286 doses. Just one patient showed a durable partial response over 16 months of treatment, while nine participants had stable disease. Reductions in tumours were seen in eight patients.
Just one patient showed a durable partial response over 16 months of treatment
